文献速递淋巴瘤

伯基特淋巴瘤国际预后指数(BL-IPI)的建立与验证

Burkitt Lymphoma International Prognostic Index.
PubMed 文献 · J Clin Oncol · 2021-01-27

该研究基于美国2009-2018年633例接受免疫化疗的成人伯基特淋巴瘤患者数据,建立并外部验证了BL-IPI。该指数由年龄≥40岁、体能状态≥2、乳酸脱氢酶>3倍正常上限和中枢神经系统受累四个等权重因素组成,将患者分为低、中、高危三组,3年无进展生存率分别为92%、72%、53%,验证队列结果一致。

要点

  • BL-IPI包含年龄≥40岁、ECOG≥2、LDH>3倍正常上限、CNS受累四个等权重危险因素。
  • 低危(0个因素)、中危(1个因素)、高危(≥2个因素)3年PFS分别为92%、72%、53%。
  • 高危组标准治疗预后欠佳,应考虑创新治疗方法。

核心结论

  • BL-IPI能稳健区分成人伯基特淋巴瘤的生存,适用于预后判断和试验分层。
  • 高危组标准治疗结局欠佳,应考虑创新治疗策略。

研究设计与样本

  • 研究采用真实世界数据建立BL-IPI,推导队列为美国2009-2018年接受免疫化疗的633例成人BL患者。
  • 外部验证队列为欧洲、加拿大和澳大利亚2004-2019年治疗的457例患者。

主要发现

  • 推导队列中年龄≥40岁、体能状态≥2、LDH>3倍正常上限、CNS受累被选为等权重独立预后因素。
  • 推导队列低、中、高危组分别占18%、36%、46%,3年PFS分别为92%、72%、53%,3年OS分别为96%、76%、59%。
  • 验证队列低、中、高危组3年PFS分别为96%、82%、63%,患者特征和分组比例与推导队列一致。
  • 该指数不受HIV状态、分期或一线化疗方案影响。

关键数值与推荐

  • BL-IPI危险因素:年龄≥40岁、体能状态≥2、血清LDH>3倍正常上限、CNS受累,各计1分。
  • 低危:0个因素;中危:1个因素;高危:≥2个因素。

临床怎么用

  • BL-IPI可用于成人BL患者的预后评估和临床试验风险分层。
  • 对≥2个危险因素的高危患者,可考虑纳入创新治疗策略的临床试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Burkitt lymphoma (BL) has unique biology and clinical course but lacks a standardized prognostic model. We developed and validated a novel prognostic index specific for BL to aid risk stratification, interpretation of clinical trials, and targeted development of novel treatment approaches. METHODS: We derived the BL International Prognostic Index (BL-IPI) from a real-world data set of adult patients with BL treated with immunochemotherapy in the United States between 2009 and 2018, identifying candidate variables that showed the strongest prognostic association with progression-free survival (PFS). The index was validated in an external data set of patients treated in Europe, Canada, and Australia between 2004 and 2019. RESULTS: In the derivation cohort of 633 patients with BL, age ≥ 40 years, performance status ≥ 2, serum lactate dehydrogenase > 3× upper limit of normal, and CNS involvement were selected as equally weighted factors with an independent prognostic value. The resulting BL-IPI identified groups with low (zero risk factors, 18% of patients), intermediate (one factor, 36% of patients), and high risk (≥ 2 factors, 46% of patients) with 3-year PFS estimates of 92%, 72%, and 53%, respectively, and 3-year overall survival estimates of 96%, 76%, and 59%, respectively. The index discriminated outcomes regardless of HIV status, stage, or first-line chemotherapy regimen. Patient characteristics, relative size of the BL-IPI groupings, and outcome discrimination were consistent in the validation cohort of 457 patients, with 3-year PFS estimates of 96%, 82%, and 63% for low-, intermediate-, and high-risk BL-IPI, respectively. CONCLUSION: The BL-IPI provides robust discrimination of survival in adult BL, suitable for use as prognostication and stratification in trials. The high-risk group has suboptimal outcomes with standard therapy and should be considered for innovative treatment approaches.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Olszewski AJ, Jakobsen LH, Collins GP, et al. Burkitt Lymphoma International Prognostic Index. J Clin Oncol. 2021. PMID: 33502927. doi:10.1200/JCO.20.03288

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。